Akash M Bhat, Rodney J Schlosser, Zachary M Soler, Vinay K Rathi
{"title":"Spending and Utilization for Chronic Rhinosinusitis With Nasal Polyps Therapies Among Commercially Insured Beneficiaries.","authors":"Akash M Bhat, Rodney J Schlosser, Zachary M Soler, Vinay K Rathi","doi":"10.1002/lary.32063","DOIUrl":null,"url":null,"abstract":"<p><p>The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP-specific spending varied widely by prescription drug among commercially insured patients, ranging from $7050 (EDS-FLU) to $28,324 (dupilumab). Condition-specific costs owed out-of-pocket ranged from $1036 (other drugs) to $3549 (mepolizumab).</p>","PeriodicalId":49921,"journal":{"name":"Laryngoscope","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laryngoscope","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/lary.32063","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
The Food and Drug Administration (FDA) recently approved several novel therapies to treat chronic rhinosinusitis with nasal polyps (CRSwNP), though high prices may burden patients and payers. CRSwNP-specific spending varied widely by prescription drug among commercially insured patients, ranging from $7050 (EDS-FLU) to $28,324 (dupilumab). Condition-specific costs owed out-of-pocket ranged from $1036 (other drugs) to $3549 (mepolizumab).
期刊介绍:
The Laryngoscope has been the leading source of information on advances in the diagnosis and treatment of head and neck disorders since 1890. The Laryngoscope is the first choice among otolaryngologists for publication of their important findings and techniques. Each monthly issue of The Laryngoscope features peer-reviewed medical, clinical, and research contributions in general otolaryngology, allergy/rhinology, otology/neurotology, laryngology/bronchoesophagology, head and neck surgery, sleep medicine, pediatric otolaryngology, facial plastics and reconstructive surgery, oncology, and communicative disorders. Contributions include papers and posters presented at the Annual and Section Meetings of the Triological Society, as well as independent papers, "How I Do It", "Triological Best Practice" articles, and contemporary reviews. Theses authored by the Triological Society’s new Fellows as well as papers presented at meetings of the American Laryngological Association are published in The Laryngoscope.
• Broncho-esophagology
• Communicative disorders
• Head and neck surgery
• Plastic and reconstructive facial surgery
• Oncology
• Speech and hearing defects